Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by StockNews.com

StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report released on Saturday. The firm issued a sell rating on the stock.

Ayala Pharmaceuticals Trading Up 12.7 %

Shares of ADXS stock opened at $0.71 on Friday. The firm’s fifty day moving average price is $0.74 and its two-hundred day moving average price is $0.79. Ayala Pharmaceuticals has a 1 year low of $0.51 and a 1 year high of $1.95.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.